Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000178430 | SCV000230509 | uncertain significance | not provided | 2015-05-27 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000178430 | SCV001148724 | uncertain significance | not provided | 2019-05-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002054116 | SCV002465521 | likely benign | Kabuki syndrome | 2023-12-23 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004528949 | SCV004111363 | uncertain significance | KMT2D-related disorder | 2023-02-07 | criteria provided, single submitter | clinical testing | The KMT2D c.13588G>A variant is predicted to result in the amino acid substitution p.Asp4530Asn. This variant has been reported in the heterozygous state in an individual with global developmental delay, autism spectrum disorder, aphasia, distinctive craniofacial features, strabismus, and cardiovascular defects (Blackburn et al. 2017. PubMed ID: 28057753). This variant is reported in 0.0062% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/12-49424759-C-T) and has conflicting interpretations of likely benign and uncertain in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/197411/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |